Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/SELLAS-LIFE-SCIENCES-GROU-39742686/news/SELLAS-gibt-die-Verabreichung-des-ersten-Patienten-in-der-Phase-Ib-II-Studie-mit-SLS009-GFH009-bei-45042957/?utm_source=whatsapp&utm_medium=social&utm_campaign=share